Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many mechanism-of-action and general formulation statements align with the label, but multiple claims are unsupported or materially incomplete versus the label (notably indications, specific cautions/contraindications, and adverse reactions). Several non-label assertions about effects of loperamide are not supported in the provided prescribing information.
Category Scores
Accurate Statements
Imodium suppository is a suppository form of Imodium (loperamide).
Provided label text describes IMODIUM (loperamide hydrochloride) but does not mention suppository; however, it is plausible as a formulation name match. No explicit label support for “suppository,” but “IMODIUM (loperamide hydrochloride)” is label-supported.
A suppository form of Imodium (loperamide) is used to treat diarrhea.
Label indicates control/symptomatic relief of acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease (and reducing ileostomy discharge).
Loperamide works by slowing down the movement of the gut.
Clinical pharmacology: slows intestinal motility; reduces peristalsis; increases intestinal transit time.
Slowing gut movement allows more time for water and electrolytes to be absorbed from stool.
Clinical pharmacology: reduces loss of fluid and electrolytes; diminishes loss of fluid and electrolytes.
By allowing more time for absorption, stool becomes firmer and less frequent.
Clinical pharmacology: increases viscosity and bulk density; reduces daily fecal volume.
Loperamide acts directly on intestinal muscles.
Label describes effects in gut wall and reducing peristalsis/tone of anal sphincter; however it does not explicitly state “intestinal muscles.” Partial mechanistic alignment.
The suppository formulation of Imodium is designed for rectal administration.
Provided label excerpts do not specifically state rectal administration for suppositories.
Suppositories can be useful when oral administration is difficult or not possible.
Not supported in the provided label excerpts.
It is important to follow dosing instructions carefully with Imodium.
Provided label excerpts include dosing/administration principle (fluid/electrolyte replacement) and contraindication/precautions; explicit instruction to follow dosing instructions is not directly stated.
Loperamide is a synthetic opioid derivative.
Not supported in the provided label excerpts.
Other antidiarrheals may have different mechanisms of action or side effect profiles.
Not supported in the provided label excerpts.
Imodium is a brand name for loperamide.
Label: IMODIUM (loperamide hydrochloride).
Unsupported Statements
Imodium suppository is a suppository form of Imodium (loperamide).
Label excerpt does not mention suppository formulation; only IMODIUM (loperamide hydrochloride) generally.
The suppository formulation of Imodium is designed for rectal administration.
No explicit statement in provided label excerpts.
Suppositories can be useful when oral administration is difficult or not possible.
No explicit statement in provided label excerpts.
Suppositories can be useful in cases of severe vomiting when oral administration is difficult or not possible.
No explicit statement in provided label excerpts.
Suppositories can be useful when a person cannot swallow medications.
No explicit statement in provided label excerpts.
Common side effects of Imodium can include constipation, dizziness, drowsiness, and nausea.
Adverse reactions section in provided label excerpt is empty; only patient information mentions tiredness, dizziness, or drowsiness may occur and advises caution driving.
Serious side effects of Imodium can occur, particularly with overuse or misuse.
Label excerpt discusses contraindications/warnings and overdose management, but does not support the specific framing about misuse as the cause of serious side effects.
Dosage instructions for Imodium suppositories are typically provided with the product packaging or by a healthcare professional.
No explicit support in provided label excerpts.
It is crucial to adhere to dosing instructions to avoid potential complications.
No explicit statement in provided label excerpts.
Loperamide acts peripherally on the gut.
Label indicates binding to opiate receptor in gut wall and effects on motility; the term “peripherally” is not explicitly stated.
Loperamide does not typically cause central nervous system effects at standard doses.
Not supported in provided label excerpts.
Loperamide does not typically cause pain relief at standard doses.
Not supported in provided label excerpts.
Janssen Pharmaceuticals originally developed and marketed Imodium.
No manufacturer/developer history in provided label excerpts.
Contradictions
Low
AI Statement
A suppository form of Imodium (loperamide) is used to treat diarrhea.
Label Reference
Indications: IMODIUM indicated for acute nonspecific diarrhea, chronic diarrhea associated with inflammatory bowel disease, and reducing ileostomy discharge volume. The statement is overly broad and omits specific labeled subtypes/indication limits.
Important Omissions
Label-specific indications beyond generic “diarrhea” (e.g., acute nonspecific diarrhea, chronic diarrhea associated with inflammatory bowel disease, and reducing ileostomy discharge volume).
Importance:
Moderate
Key contraindications: hypersensitivity; abdominal pain in absence of diarrhea; not recommended in infants <24 months; not for acute dysentery, acute ulcerative colitis, bacterial enterocolitis (Salmonella/Shigella/Campylobacter), or pseudomembranous colitis.
Importance:
High
Drug interaction precautions (P-glycoprotein inhibitors such as quinidine and ritonavir; saquinavir monitoring).
Importance:
High
Warnings to discontinue promptly with constipation, abdominal distention, or ileus; symptomatic-only treatment; fluid/electrolyte replacement; AIDS patient stopping at earliest signs of abdominal distention; caution in young children.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI output omits multiple label contraindications and key warnings (e.g., not for dysentery/ulcerative colitis/bacterial enterocolitis/pseudomembranous colitis; discontinue with constipation/distention/ileus; fluid/electrolyte replacement; interaction cautions). It also includes adverse-effect claims not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Missing/omitted label contraindications and drug interaction warnings; unsupported safety/side-effect statements; indication description is overly broad compared with labeled subtypes.
Suggested Improvement
Restrict indication language to the exact labeled indications; include the contraindications list and major warnings/precautions (fluid/electrolyte replacement; avoid use when peristalsis inhibition should be avoided; discontinue with constipation/distention/ileus; AIDS-specific stop rule; caution in young children); and add label drug interaction precautions (quinidine/ritonavir; saquinavir monitoring). Remove side-effect claims not supported by the provided label excerpts.